PT-141, also called bremelanotide, is a prescription sexual-health peptide—not an over-the-counter supplement to buy for human use on Amazon. FDA-approved bremelanotide is Vyleesi, indicated for certain premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Other uses, including erectile dysfunction, are off-label discussions that need clinician review 1.
Wondering if PT-141 is right for you? Take the 3-min clinical quiz.
See if you qualify →Can you buy PT-141 peptide on Amazon?
PT-141 may appear in Amazon and marketplace searches, but a listing is not the same as prescribed bremelanotide. For human use, look for a licensed clinician’s evaluation, a valid prescription, and dispensing by a licensed pharmacy. FDA guidance warns against online sources that sell prescription drugs without a prescription or do not offer a legitimate pharmacy contact process 5.
Why Amazon search results can be confusing
A search for “PT-141 peptide” can return supplements, skin-care products, research-use materials, sponsored listings, podcasts, and products that merely use similar words. That does not establish that a listing contains bremelanotide, is intended for human use, or has been handled under prescription-pharmacy controls.
Bremelanotide is a drug-like peptide, not an herb or a general wellness vitamin. The FDA-approved product has a specific indication, contraindications, warnings, and prescribing information 1. A listing without medical review cannot provide that clinical context.
Research peptides, supplements, and prescription medications are not the same
| Category | What it means | Human-use oversight | Key concern |
|---|---|---|---|
| Prescription bremelanotide | FDA-approved Vyleesi injection for a labeled indication | Prescriber, pharmacy, product label, and FDA-reviewed safety information | Appropriate only for people who meet clinical criteria |
| Compounded PT-141 nasal spray | A compounded medication made under an individual prescription | Licensed clinician review and state-licensed 503A pharmacy dispensing | Not FDA-approved; FDA has not evaluated the compounded formulation for safety, effectiveness, or quality 6 |
| Research-use peptide | Material represented for laboratory research rather than patient treatment | No patient-specific prescription evaluation | It is not a substitute for medication dispensed for human use |
| Supplement listing | A dietary supplement or unrelated item using similar keywords | No prescription process | It may not contain PT-141 and is not FDA-approved to treat HSDD or ED |
Why a marketplace listing should not replace a licensed medical evaluation
Low desire, arousal concerns, and erectile dysfunction can overlap with medication effects, depression, anxiety, relationship stress, diabetes, high blood pressure, vascular disease, hormonal changes, pelvic pain, and sleep problems. The American Urological Association recommends an evaluation for medical and psychosocial contributors to ED rather than self-treating a symptom without context 4.
What is PT-141 used for?
PT-141 is bremelanotide, with one FDA-approved sexual-health indication: Vyleesi for acquired, generalized HSDD in certain premenopausal women 1. It has also been investigated for erectile dysfunction, but that is not an FDA-approved use and has a different evidence base.
Approved use: bremelanotide for acquired, generalized HSDD
HSDD is a diagnosis involving low sexual desire that causes marked distress or relationship difficulty. In this label, “acquired” means the problem began after a period of typical sexual desire, while “generalized” means it is not limited to one partner, situation, or type of sexual activity 1.
In the RECONNECT phase 3 trials, premenopausal women with HSDD receiving bremelanotide had greater improvement in validated desire and distress measures than participants receiving placebo. Nausea was also common, so the trial results do not mean the medication is right for every person; individual results vary 2.
Off-label interest: erectile dysfunction and sexual arousal concerns
Early human research evaluated intranasal PT-141 in men with erectile dysfunction, including men who had not responded well to sildenafil. Those studies helped establish why the peptide drew interest, but they did not create an FDA-approved indication for ED 3.
What PT-141 is not
PT-141 is not a general performance supplement or an over-the-counter libido booster. The Vyleesi label includes warnings about temporary blood-pressure increases and reduced heart rate after administration, along with contraindications for uncontrolled hypertension and known cardiovascular disease 1.
How does PT-141 work in the body?
PT-141 works through melanocortin receptors, including pathways associated with sexual desire and arousal in the central nervous system. Its mechanism differs from PDE5 inhibitors such as Viagra and Cialis, but a different mechanism does not guarantee benefit for a specific person 3.
Melanocortin receptor agonist mechanism
Bremelanotide is a cyclic heptapeptide and melanocortin receptor agonist. It has activity at melanocortin receptors, including the melanocortin-4 receptor, which has a role in central sexual-arousal signaling 3.
Central nervous system pathway versus blood-flow medications
Sildenafil, known as Viagra, and tadalafil, known as Cialis, are PDE5 inhibitors. They support nitric-oxide/cGMP signaling in penile tissue and are used for erectile dysfunction under their FDA-approved labeling. PT-141 was developed around a central arousal pathway instead 4.
Why mechanism does not guarantee benefit for every person
A plausible mechanism is not the same as a predictable result. In bremelanotide studies and labeling, potential benefits were weighed alongside nausea, flushing, headache, and blood-pressure effects 1. Symptoms also may have causes that a melanocortin-targeting medication does not address.
How is PT-141 different from Viagra and Cialis?
PT-141 and PDE5 inhibitors are different drug classes. PDE5 inhibitors are guideline-supported options for many men with ED, while PT-141 for ED remains an off-label conversation. The right evaluation starts with the symptom, possible cause, medical history, and safety risks—not a claim that one option is universally better 4.
| Medication type | Examples | Main pathway | FDA-approved sexual-health use | Important concerns |
|---|---|---|---|---|
| Melanocortin receptor agonist | Bremelanotide / PT-141; Vyleesi | Central melanocortin arousal pathways | Vyleesi: acquired, generalized HSDD in certain premenopausal women | Nausea, flushing, headache, temporary blood-pressure increase, heart-rate reduction |
| PDE5 inhibitor | Sildenafil / Viagra; tadalafil / Cialis | Nitric-oxide/cGMP blood-flow pathway | ED and other labeled uses depending on the medication | Nitrates can cause dangerous low blood pressure; other warnings vary by drug |
| Hormone-related treatment | Depends on diagnosis | Depends on the hormone pathway | Depends on condition and product | Requires diagnosis-specific review and is not appropriate for every symptom |
| Over-the-counter supplement | Varies widely | Often uncertain or weakly supported | Not FDA-approved to treat ED or HSDD | Interactions, undeclared ingredients, and quality can be concerns |
Different mechanisms mean different safety questions
Bremelanotide labeling warns about transient blood-pressure increases and reduced heart rate after use. PDE5 inhibitors have a different safety profile, including a serious low-blood-pressure risk when used with nitrates 1 4. A clinician needs to review the full medication list and cardiovascular history before deciding what is appropriate.
3-min quiz
Considering PT-141 nasal spray?
Chia offers PT-141 Nasal as a compounded nasal spray, with plans currently starting at $159/mo. Start with an online health questionnaire reviewed by a licensed US provider. A prescription requires a medical evaluation and is not guaranteed. Compounded drugs are not FDA-approved 6.
Is PT-141 on Amazon safe or legitimate?
PT-141 listings on a marketplace should not be assumed to be legitimate medication for human use. The important question is whether a licensed clinician evaluated the patient, a valid prescription was issued, and a licensed pharmacy dispensed the exact medication with appropriate labeling and follow-up 5.
Why product identity, handling, and storage matter
Prescription drugs and compounded preparations require controls around sourcing, preparation, labeling, storage, and dispensing. FDA explains that compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing 6. That makes the pharmacy source and clinician oversight especially important.
Why research-use products are not the same as prescribed medication
“Research use only” language means a product is not represented as a medication for patient treatment. It does not provide a patient-specific diagnosis, review of contraindications, counseling about adverse effects, or a prescription-pharmacy follow-up process.
Red flags to watch for
- No prescription process or licensed clinician review.
- No identifiable pharmacy source or pharmacy license information.
- Human-use promises paired with “research use only” language.
- No way to contact a pharmacist or care team about side effects.
- Unclear storage instructions, lot information, expiration or beyond-use date.
- Guaranteed claims about libido, arousal, erections, or relationship outcomes.
FDA’s BeSafeRx program advises patients to avoid online sources that do not require a prescription, do not provide access to a licensed pharmacist, or offer prices that seem too good to be true 5. For more on evaluating a peptide source, read our guide to getting a peptide prescription safely and our overview of where to get peptide injections safely.
How does PT-141 nasal spray work at Chia?
At Chia, PT-141 Nasal is available only as a compounded nasal spray, with plans currently starting at $159/mo. It is accessed through a licensed-provider review, not through an Amazon-style checkout. You can review PT-141 Nasal or the Spark protocol for current details.
What Chia offers
Chia offers PT-141 Nasal only as a nasal spray. We do not offer PT-141 injections, tablets, or other PT-141 forms. Compounded PT-141 nasal spray is not FDA-approved, and its outcomes have not been evaluated by FDA 6.
| Chia option | Form | Current starting price | What to know |
|---|---|---|---|
| PT-141 Nasal | Compounded nasal spray | From $159/mo | Available after licensed-provider review when clinically appropriate |
| Spark | PT-141 Nasal protocol | From $159/mo | A Chia protocol centered on PT-141 Nasal |
What the online process includes
Care at Chia is 100% online. You complete a short health questionnaire, and a licensed US provider reviews your health history and decides whether treatment is clinically appropriate. If prescribed, medication is compounded in the US by a state-licensed 503A compounding pharmacy and shipped to your door.
Dosing and follow-up are provider-guided. Patients can message their care team through the patient portal between visits. If you use an AI agent to organize care, DoctorMCP at mcp.chia.health can route patients to Chia’s prescription pathway and eligibility quiz; it does not replace a medical evaluation.
What risks and side effects should you discuss?
Nausea is one of the most important bremelanotide side effects to discuss, along with flushing, headache, vomiting, and blood-pressure effects. The FDA-approved Vyleesi label also lists cardiovascular contraindications, which is why PT-141 needs a clinician-led risk review 1.
Commonly discussed side effects
The Vyleesi label lists nausea, flushing, headache, vomiting, and injection-site reactions among common adverse reactions. In the RECONNECT trials, nausea was the most common adverse event and was more frequent with bremelanotide than placebo 1 2.
Blood-pressure and heart-history considerations
The FDA label states that bremelanotide can temporarily increase blood pressure and reduce heart rate after dosing. It is contraindicated for people with uncontrolled hypertension or known cardiovascular disease 1. Those label findings apply to FDA-approved Vyleesi, but they are still important safety context when a clinician considers the active ingredient in another formulation.
Why sexual-health symptoms deserve a full evaluation
ED can be associated with diabetes, vascular disease, high blood pressure, sleep apnea, depression, alcohol use, medication side effects, low testosterone, and relationship factors. AUA guidance recommends a medical, sexual, and psychosocial history, focused physical examination, and appropriate testing when evaluating ED 4.
What should you ask before using PT-141?
Before considering PT-141, ask what symptom is being addressed and whether the planned use is FDA-approved or off-label. It is also reasonable to ask about the evidence for the specific route, possible side effects, the pharmacy source, and the follow-up plan.
- 1What diagnosis or concern are we addressing: HSDD, ED, low arousal, medication effects, hormone changes, or something else?
- 2Is this use FDA-approved or off-label?
- 3What human evidence supports the form and route being considered?
- 4What side effects should I watch for, including nausea, flushing, headache, and blood-pressure changes?
- 5Does my blood-pressure, heart, medication, or mental-health history make PT-141 a poor fit?
- 6What state-licensed 503A pharmacy is compounding the medication?
- 7How will follow-up work if I have side effects or do not see benefit?
Other treatments are not interchangeable with PT-141 simply because they are peptides. For example, Chia also offers Sermorelin and the Foundation Longevity protocol, but they are separate treatments for different goals and are not substitutes for evaluation of HSDD or ED.
3-min quiz
Start with a clinical review
If you are considering PT-141 nasal spray, a Chia online visit lets a licensed US provider review your health history and decide whether PT-141 Nasal or the Spark protocol is appropriate. A prescription requires a medical evaluation and is not guaranteed. Compounded drugs are not FDA-approved 6.
PT-141 and Amazon FAQ
PT-141 is another name for bremelanotide. FDA-approved bremelanotide, sold as Vyleesi, is for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women. Other uses may be off-label 1.
No. FDA-approved bremelanotide is indicated for acquired, generalized HSDD in certain premenopausal women. Erectile dysfunction is not an FDA-approved indication for PT-141 1.
PT-141 intended for human use should go through a licensed clinician and prescription process. Marketplace and research-use products should not be treated as equivalent to medication dispensed by a licensed pharmacy 5.
No. Chia offers PT-141 Nasal only as a compounded nasal spray. Chia does not offer PT-141 injections, tablets, or other PT-141 forms.
Yes. Chia offers clinician-reviewed compounded PT-141 Nasal, with plans currently starting at $159 per month. A licensed provider must determine whether treatment is appropriate, and a prescription is not guaranteed. Compounded PT-141 Nasal is not FDA-approved 6.
References
- 1.U.S. Food and Drug Administration. Vyleesi (bremelanotide injection) Prescribing Information. 2019.
- 2.Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstetrics & Gynecology. 2019.
- 3.Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research. 2004.
- 4.Burnett AL, Nehra A, Breau RH, et al. Erectile Dysfunction: AUA Guideline. American Urological Association. 2018.
- 5.U.S. Food and Drug Administration. BeSafeRx: Know Your Online Pharmacy. 2024.
- 6.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. 2024.
- 7.U.S. Food and Drug Administration. FDA warns consumers about hidden drug ingredients in products marketed for sexual enhancement. 2024.
- 8.U.S. Food and Drug Administration. Understanding the Risks of Compounded Drugs. 2024.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if PT-141 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.


